Showcasing funding given through our Prevention and Risk Reduction Fund
In 2017/18 we joined forces with the Wellcome Trust, seven universities and four pharmaceutical companies to become part of the £8m Neuroimmunology of Mood disorders and Alzheimer’s disease (NIMA) Consortium. This collaborative effort is investigating whether diseases like Alzheimer’s and mood disorders such as depression could be treated by targeting the immune system, which is believed to play a key role in both conditions. With your support, we contributed £300,000 to the initiative to fund a study using PET scans that will help take this work into clinical trials.